Page 2 - Suzy Dilly News Today : Breaking News, Live Updates & Top Stories | Vimarsana

27 April 2021 | 08:46am StockMarketWire.com - Clinical-stage drug development company ValiRx narrowed full-year losses after it cut back on R&D and administrative spending. Pre-tax losses for the year through December amounted to £1.54 million, compared to year-on-year losses of £2.7 million. The company said it had launched a new strategy and implemented structural changes to develop 'a risk-diversified approach to early-stage drug development'. A phase 1/2 clinical trial close out and reporting of lead asset VAL201 had demonstrated good safety and tolerability and early indications of eff...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...